SensorionFRA:RFM +17.11%24 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, Sensorion ranks worse than 142450% on this metric.
The historical rank and industry rank for Sensorion's Days Payable or its related term are showing as below:
During the past 13 years, Sensorion's highest Days Payable was 1394.98. The lowest was 1119.51. And the median was 1257.25.
FRA:RFM's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56 * Ranked among companies with meaningful Days Payable only.
Sensorion's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Sensorion Days Payable Related Terms
Sensorion Days Payable Historical Data
* Premium members only.
The historical data trend for Sensorion's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RFM vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Sensorion's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensorion Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sensorion's Days Payable distribution charts can be found below:
* The bar in red indicates where Sensorion's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sensorion's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensorion (FRA:RFM) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sensorion and its competitors. Over the past decade, Sensorion's Days Payable has ranged from 1,119.51 to 1,394.98. According to the industry distribution chart, Sensorion ranks #999999 out of 702 companies in the Biotechnology industry.
Is Sensorion's Days Payable too high?
Sensorion's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,119.51 to a high of 1,394.98. Based on the distribution chart, Sensorion ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sensorion has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sensorion ranks #999999 out of 702 companies for Days Payable. This places Sensorion in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Sensorion's own Days Payable has ranged from 1,119.51 to 1,394.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sensorion and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sensorion's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current Days Payable of 0.00. The current Days Payable is 0.00. Sensorion's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
24GF Score
Get the complete analysis for FRA:RFM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RFM has been successfully added to your 
